Search company, investor...

Circassia Holdings

circassia.co.uk

Founded Year

1998

Stage

IPO | IPO

Total Raised

$98M

Date of IPO

3/13/2014

Market Cap

0.15B

About Circassia Holdings

Circassia is focused on developing and commercialising a range of immunotherapies for the treatment of allergy and we have made significant progress since our establishment in 2006. The company's lead product, a new treatment for cat allergy, is currently in a phase III registration study and the company has an exciting portfolio of products, including three that have successfully completed clinical proof-of-concept phase IIb studies, designed to treat a broad range of seasonal and perennial allergies.

Headquarters Location

Northbrook House, Robert Robinson Avenue The Oxford Science Park

Oxford, England, OX4 4GA,

United Kingdom

+44 (0)1865 405560

Missing: Circassia Holdings's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Circassia Holdings's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Circassia Holdings

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Circassia Holdings is included in 3 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Circassia Holdings Patents

Circassia Holdings has filed 1 patent.

The 3 most popular patent topics include:

  • Biomaterials
  • Crystals
  • Nanomaterials
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/15/2015

12/4/2018

Glucocorticoids, Beta blockers, Pregnanes, Muscarinic antagonists, Fluoroarenes

Grant

Application Date

9/15/2015

Grant Date

12/4/2018

Title

Related Topics

Glucocorticoids, Beta blockers, Pregnanes, Muscarinic antagonists, Fluoroarenes

Status

Grant

Circassia Holdings Frequently Asked Questions (FAQ)

  • When was Circassia Holdings founded?

    Circassia Holdings was founded in 1998.

  • Where is Circassia Holdings's headquarters?

    Circassia Holdings's headquarters is located at Northbrook House, Robert Robinson Avenue, Oxford.

  • What is Circassia Holdings's latest funding round?

    Circassia Holdings's latest funding round is IPO.

  • How much did Circassia Holdings raise?

    Circassia Holdings raised a total of $98M.

  • Who are the investors of Circassia Holdings?

    Investors of Circassia Holdings include Touchstone Innovations, Invesco Perpetual, Lansdowne Partners, Stonehage Fleming, Goldman Sachs and 3 more.

  • Who are Circassia Holdings's competitors?

    Competitors of Circassia Holdings include Genable Technologies, EGEN, Quincy Bioscience, Jennerex Biotherapeutics, Sonexa Therapeutics and 10 more.

Compare Circassia Holdings to Competitors

M
Myelos Corporation

Savient Pharmaceuticals is a specialty biopharmaceutical company engaged in developing and commercializing pharmaceutical products that target unmet medical needs in rheumatology and other specialty niche medical markets. The company's focus is on the company's biologic product candidate, Puricase (pegloticase) that has been developed for treatment-failure gout (TFG).

a
arGentis Pharmaceuticals

arGentis Pharmaceuticals is a diversified specialty biopharmaceutical company seeking to license and commercialize therapies with demonstrated proof of concept for chronic diseases.

B
Bikam Pharmaceuticals

BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.

S
Sound Pharmaceuticals

Sound Pharmaceuticals (SPI) is a biopharmaceutical company that develops prescription drugs that will enable doctors and patients to prevent and treat hearing loss, a disease that affects over 30 to 40 million Americans. It was founded in 2002 and is based in Seattle, Washington.

J
Janus Pharmaceuticals

Janus Pharmaceuticals Inc. (Janus) is a specialty pharmaceutical company identifying, acquiring and aggressively developing topical prescription products for treatment of skin infections. Determined to be the "Dermal Alternative", Janus has already established a strong intellectual property portfolio for topical anti-infective compounds that would be rapidly commercialized through fast regulatory pathways. Led by an accomplished management team and board located in the US and Japan, Janus has trans-Pacific network and resources in the biopharmaceutical industry.

V
VidaGene

VidaGene,Inc., is a biopharmaceutical company that aims to develop pharmaceuticals based on modulation of the vitamin D receptor (VDR). VidaGene seeks to develop entirely new VDR modulators for large pharmaceutical markets such as cancer-related thrombosis, osteoporosis and psoriasis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.